Eight non-splenectomized patients with corticosteroid-refractory idiopathic thrombocytopenic purpura (ITP) were treated with low-dose vincristine (1 mg/week up to a total dose of 4 mg). Complete remission was achieved in 2 cases and partial remission in 3. Bleeding stopped in one patient who failed to remit. No statistical relationship was found between the response to vincristine and the duration of the disease or the corticosteroid-therapy. Side effects were only observed in one patient. By comparing these results with those reported in the literature, it can be inferred that low-dose vincristine may be useful in the management of corticosteroid-refractory ITP.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2426022PMC
http://dx.doi.org/10.1136/pgmj.56.660.711DOI Listing

Publication Analysis

Top Keywords

low-dose vincristine
12
corticosteroid-refractory idiopathic
8
idiopathic thrombocytopenic
8
thrombocytopenic purpura
8
purpura itp
8
non-splenectomized patients
8
vincristine treatment
4
treatment corticosteroid-refractory
4
itp non-splenectomized
4
patients non-splenectomized
4

Similar Publications

Article Synopsis
  • * Our experiments included cytotoxicity assays on various cancer cell lines, revealing that perifosine selectively sensitized P-gp-overexpressing MCF-7/ADR and KBV20C cells, unlike other tested Akt inhibitors which were more effective on non-resistant cells.
  • * The mechanism behind perifosine's action involved increased apoptosis and cell cycle arrest in resistant MCF-7/ADR cells, yet it did not significantly inhibit P-gp activity, indicating that the drug
View Article and Find Full Text PDF

Advances in Primary Central Nervous System Lymphoma.

Curr Neurol Neurosci Rep

November 2024

Department of Neurology and Neurological Sciences, Stanford University School of Medicine, 875 Blake Wilbur, MC 6510, Stanford, Palo Alto, CA, 94305, USA.

Article Synopsis
  • This article reviews the importance of optimal initial management in primary CNS lymphoma (PCNSL) and its potential impact on long-term patient outcomes.
  • Recent advances include using genomic analysis of CSF cell-free DNA for diagnosis and improved treatment options for younger patients, where chemotherapy has shown high cure rates.
  • In contrast, older patients still face poor outcomes, prompting investigations into new therapies and consolidation options like low-dose radiation, while ongoing clinical trials aim to address their treatment needs.
View Article and Find Full Text PDF
Article Synopsis
  • Acute lymphoblastic leukemia (ALL) relies on interactions with non-cancerous bone marrow stromal cells for its survival, highlighting the importance of understanding this relationship for potential treatments.
  • The study investigated whether gap junctions—cellular channels that facilitate communication between cells—are essential for the survival of leukemia cells when in contact with stromal cells, using various experimental techniques.
  • Results indicated that intact gap junctions are crucial for leukemia cell survival; disruptions to these connections decreased their viability, suggesting that targeting gap junctions could be a new therapeutic strategy for treating ALL.*
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to identify factors that affect delays in chemotherapy for children with Burkitt lymphoma and how these delays impact patient outcomes.
  • It analyzed clinical data from 591 children in China, looking at various characteristics and the reasons behind chemotherapy delays, such as severe infections and bone marrow suppression.
  • The findings showed that 12.4% of patients experienced chemotherapy delays, and the overall survival rate was high at 92.5%, suggesting that while delays are problematic, most patients still fared well.
View Article and Find Full Text PDF

Cancer chemotherapy increases the risk of thrombosis; however, the mechanisms underlying this thrombosis are not completely understood. Plasminogen activator inhibitor (PAI)-1 is a key molecule in the fibrinolytic system that inhibits tissue plasminogen activator and urokinase, which converts plasminogen into plasmin; therefore, excess PAI-1 increases the risk of thrombosis. In this study, we investigated whether temporary treatment of the human luminal A-type breast cancer cell line MCF-7 with antitumor drugs clinically used for breast cancer therapy promotes PAI-1 production.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!